

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 8199



DEFENSE MEDICAL MATERIEL BOARD
POTOMAC ANNEX, 2300 E STREET NW.
WASHINGTON, D.C. 20390

ADDRESS REPLY TO:
STAFF DIRECTOR, DEFENSE
MEDICAL MATERIEL BOARD
AND REFER TO:

43
5420
Serial: 86
25 January 1971

MEMORANDUM

From: Chairman, FSC Class 6505 Review Committee
To: Assistant Secretary of Defense (Health and Environment)

Subj: Committee Review of Special Interest Items; Report of

Ref: (a) ASD (H&E) Memo dated 27 Oct 1970

Encl: (1) List of 30 Items Proposed for Reclassification to "LIMITED
STANDARD" with Eventual Deletion from the Federal Supply Catalog
(2) Committee Recommendations Covering "Special Interest" Items

1. In accordance with reference (a), a line item review of all FSC Class 6505 is being conducted. The modus operandi of the Committee will be review by therapeutic group as listed in the Federal Supply Catalog.

2. Because of the current interest in certain drugs, the Committee deviated from its planned order of review. Enclosure (1) is a list of 30 items considered to be of "special interest", which was forwarded to the professional consultants on January 11 and 14 1971, with the proposal for reclassification to Limited Standard and ultimate deletion from the Federal Supply Catalog. Service position or appropriate comments were requested.

3. An abbreviated item review report is given below as an example of committee action:

1. 6505-890-2081 DEMETHYLCHLORTETRACYCLINE HYDROCHLORIDE TABLETS,
0.15 GRAM (DECILOMYCIN)

2. 6505-159-6575 CHLORTETRACYCLINE HYDROCHLORIDE CAPSULES, 0.25 GRAM
(AUREOMYCIN)

3. 6505-299-8276 OXYTETRACYCLINE TABLETS, 0.25 GRAM (TERRAMYCIN)

DISCUSSION: 1. Medical authorities state that the TETRACYCLINES do not differ in any essential characteristics and are essentially identical in terms of antibacterial activity. The differences in pharmacologic activity, due to molecular modifications, are relatively minor in importance.

2. Differences in costs are significant.